169 related articles for article (PubMed ID: 38010591)
1. Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
Ferri N; De Martin S; Stuart J; Traversa S; Folli F; Pappagallo M; O'Gorman C; Guidetti C; Mattarei A; Inturrisi CE; Manfredi PL
Drugs R D; 2024 Mar; 24(1):51-68. PubMed ID: 38010591
[TBL] [Abstract][Full Text] [Related]
2. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Shram MJ; Henningfield JE; Apseloff G; Gorodetzky CW; De Martin S; Vocci FL; Sapienza FL; Kosten TR; Huston J; Buchhalter A; Ashworth J; Lanier R; Folli F; Mattarei A; Guidetti C; Comai S; O'Gorman C; Traversa S; Inturrisi CE; Manfredi PL; Pappagallo M
Transl Psychiatry; 2023 Jun; 13(1):192. PubMed ID: 37286536
[TBL] [Abstract][Full Text] [Related]
3. REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.
Bifari F; Pappagallo M; Bleavins M; Traversa S; Folli F; Manfredi PL
Front Pharmacol; 2022; 13():863959. PubMed ID: 35571103
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Bettini E; Stahl SM; De Martin S; Mattarei A; Sgrignani J; Carignani C; Nola S; Locatelli P; Pappagallo M; Inturrisi CE; Bifari F; Cavalli A; Alimonti A; Pani L; Fava M; Traversa S; Folli F; Manfredi PL
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015145
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
7. Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stahl SM; De Martin S; Mattarei A; Bettini E; Pani L; Guidetti C; Folli F; de Somer M; Traversa S; Inturrisi CE; Pappagallo M; Gentilucci M; Alimonti A; Fava M; Manfredi PL
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293063
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.
Nyunt MM; Becker S; MacFarland RT; Chee P; Scarborough R; Everts S; Calandra GB; Hendrix CW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):559-65. PubMed ID: 18362694
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
10. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
12. Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Fava M; Stahl SM; De Martin S; Mattarei A; Bettini E; Comai S; Alimonti A; Bifari F; Pani L; Folli F; Guidetti C; Furlan A; Sgrignani J; Locatelli P; Cavalli A; O'Gorman C; Traversa S; Inturrisi CE; Pappagallo M; Manfredi PL
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1463-1476. PubMed ID: 36890259
[TBL] [Abstract][Full Text] [Related]
13. The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin.
Bettini E; De Martin S; Mattarei A; Pappagallo M; Stahl SM; Bifari F; Inturrisi CE; Folli F; Traversa S; Manfredi PL
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890179
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.
Yamazaki T; Desai A; Goldwater R; Han D; Howieson C; Akhtar S; Kowalski D; Lademacher C; Pearlman H; Rammelsberg D; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):54-65. PubMed ID: 27273149
[TBL] [Abstract][Full Text] [Related]
17. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
18. Effect of Curcuma longa on CYP2D6- and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects.
Al-Jenoobi FI; Al-Thukair AA; Alam MA; Abbas FA; Al-Mohizea AM; Alkharfy KM; Al-Suwayeh SA
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):61-6. PubMed ID: 24510399
[TBL] [Abstract][Full Text] [Related]
19. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
Henningfield J; Gauvin D; Bifari F; Fant R; Shram M; Buchhalter A; Ashworth J; Lanier R; Pappagallo M; Inturrisi C; Folli F; Traversa S; Manfredi PL
Sci Rep; 2022 Jul; 12(1):11389. PubMed ID: 35794162
[TBL] [Abstract][Full Text] [Related]
20. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Fava M; Stahl S; Pani L; De Martin S; Pappagallo M; Guidetti C; Alimonti A; Bettini E; Mangano RM; Wessel T; de Somer M; Caron J; Vitolo OV; DiGuglielmo GR; Gilbert A; Mehta H; Kearney M; Mattarei A; Gentilucci M; Folli F; Traversa S; Inturrisi CE; Manfredi PL
Am J Psychiatry; 2022 Feb; 179(2):122-131. PubMed ID: 34933568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
